ClinicalTrials.gg
TerminatedNCT06704724Updated May 22, 2026

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

A Phase 1 interventional study of PF-07985045 and Gemcitabine in Carcinoma, Pancreatic Ductal, Colorectal Neoplasms and Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Terminated at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Carcinoma, Pancreatic Ductal with a site in United States — 5 open to participants now, 10 under way, 1 of them phase 3. Carcinoma, Pancreatic Ductal · United States.

Enrollment
19th of 26
30 · median 97
Started
2024
with 2 others
Phase 1
9 of 30
none open now
Registered
27th of 30
by date
Lead sponsor
4 of 30
Pfizer

Among the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, this one is the 19th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 1, and was the 27th registered.

Carcinoma, Pancreatic Ductal

57 studies on the registry are indexed under Carcinoma, Pancreatic Ductal; 10 are open to participants now.

Browse Carcinoma, Pancreatic Ductal studies →

Open to participants now

5 of the 30 studies in Carcinoma, Pancreatic Ductal with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Carcinoma, Pancreatic Ductal studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Carcinoma, Pancreatic Ductal with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.

This study also aims to find the best amount of study medication.

This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:

  • are advanced (cancer that doesn't disappear or stay away with treatment) and
  • have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).

This includes (but limited to) the following cancer types:

  • Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
  • Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.
  • Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.

All participants in this study will take the study medication (PF-07985045) as pill by mouth. This will be repeated for 21-day or 28-day cycles.

Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle.

Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding.

The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.

Participants will be in this study for up to 4 years. During this time, the participants will come into the clinic for 1 to 4 times in each 21-day or 28-day cycle. After the participants have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing

03

Conditions studied

  • Carcinoma, Pancreatic Ductal
  • Colorectal Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Carcinoma, Pancreatic Ductal
  • Carcinoma, Ductal, Pancreatic
  • Duct-Cell Carcinoma of the Pancreas
  • Duct-Cell Carcinoma, Pancreas
  • Ductal Carcinoma of the Pancreas
  • Pancreatic Duct Cell Carcinoma
  • Pancreatic Ductal Carcinoma
  • pancreatic ductal adenocarcinoma
  • PDAC
  • Colorectal Neoplasms
  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Tumors
  • Neoplasms, Colorectal
  • Rectal Cancer
  • Colon Cancer
  • CRC
  • MSS CRC
  • Carcinoma, Non-Small-Cell Lung
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Carcinoma
  • Non-Small-Cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer
  • Lung Cancer
  • NSCLC
  • KRAS
  • KRAS gene mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of advanced, unresectable, and/or or solid tumor.

    • Note for PDAC: Only participants with the histologic type of adenocarcinoma of the pancreas are allowed to enroll. For PDAC, if loco-regional disease is present, must also have metastatic disease.
    • Note for NSCLC: If a driver mutation is present, the participant was resistant or intolerant of precision medicine therapy (eg, inhibitors of EGFR, ALK, ROS1, or others).
  • PS 0 or 1
  • Presence of at least 1 based on version 1.1 that has not been previously irradiated.
  • Documentation of mutated KRAS gene

    a. KRAS mutations of any variant except previously treated with any KRAS inhibitor

  • Part 1: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.

    1. PDAC (2-3L): Participants must have received and radiologically progressed on for metastatic pancreatic adenocarcinoma. If participants received prior or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.
    2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and/or therapy; for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.
    3. CRC (2-3L): Participants must have had only one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional.
    4. other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.
  • Part 2:

    1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of completing these forms of adjuvant treatment. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.
    2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF/VEGF receptor (VEGFR) inhibitor is optional.
    3. CRC (1L) Cohort B3: Participants must not have had prior chemotherapy for advanced or metastatic disease. Participant could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of complete of adjuvant therapy. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.
    4. NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not have received prior systemic treatment setting.
    5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.

Exclusion criteria

Exclusion Criteria:

  • Active pneumonitis/ILD, pulmonary fibrosis requiring treatment with systemic therapy. Additionally, participants in IO combinations (Cohorts C2 and C3) with history and/or active pneumonitis/ILD or pulmonary fibrosis requiring steroids are excluded from enrollment.
  • Active or history of gastrointestinal (GI) disease (including but not limited to inflammatory GI disease [eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration.
  • Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.
  • Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included >30% of the bone marrow.
  • Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including drainage catheter placement, therapeutic thoracentesis or abdominal paracentesis) is eligible.
  • Current use or have received PPIs in the last seven days prior to starting study treatment.
  • Known sensitivity or to any component of study intervention (PF-07985045, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, sasanlimab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s).
  • Hematologic abnormalities.
  • Renal impairment.
  • Hepatic abnormalities.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1 Dose Escalation

    PF-07985045 monotherapy Dose Escalation at prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045

  • Experimental
    Part 1 Cohort A1

    PF-07985045 monotherapy dose expansion in 2-3L PDAC at prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045

  • Experimental
    Part 1 Cohort B1

    PF-07985045 monotherapy dose expansion in 2-3L CRC at prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045

  • Experimental
    Part 1 Cohort C1

    PF-07985045 monotherapy dose expansion in 2-3L NSCLC at prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045

  • Experimental
    Part 1 Cohort D1

    PF-07985045 monotherapy dose expansion in other tumor types at prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045

  • Experimental
    Part 2 Cohort A2

    Combination (PF-07985045 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC. Prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045 · Combination Product: Gemcitabine · Combination Product: Nab-paclitaxel

  • Experimental
    Part 2 Cohort B2

    Combination (PF-07985045 + Cetuximab) dose escalation/expansion in 2-3L CRC Prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045 · Combination Product: Cetuximab

  • Experimental
    Part 2 Cohort B3

    Combination (PF-07985045 + FOLFOX + Bevacizumab) dose escalation/ expansion in 1L CRC Prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045 · Combination Product: Fluorouracil · Combination Product: Oxaliplatin · Combination Product: Leucovorin · Combination Product: Bevacizumab

  • Experimental
    Part 2 Cohort B4

    Combination (PF-07985045 + FOLFOX + Cetuximab) dose escalation/ expansion in 1L CRC Prescribed dose and frequency in 28-day cycles

    Drug: PF-07985045 · Combination Product: Cetuximab · Combination Product: Fluorouracil · Combination Product: Oxaliplatin · Combination Product: Leucovorin

  • Experimental
    Part 2 Cohort C2

    Combination (PF-07985045 + Pembro or sasanlimab) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%) Prescribed dose and frequency in 21-day (pembro) or 28-day (sasanlimab) cycles

    Drug: PF-07985045 · Combination Product: Pembrolizumab · Combination Product: Sasanlimab

  • Experimental
    Part 2 Cohort C3

    Combination (PF-07985045 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS) Prescribed dose and frequency in 21-day cycles

    Drug: PF-07985045 · Combination Product: Pembrolizumab · Combination Product: pemetrexed · Combination Product: Cisplatin · Combination Product: Paclitaxel · Combination Product: Carboplatin

  • Experimental
    Part 2 Cohort X

    Combination (PF-07985045 + PF-07284892) dose escalation/expansion Prescribed dose and frequency in 21-day cycles

    Drug: PF-07985045 · Combination Product: PF-07284892

Interventions

  • DrugPF-07985045

    KRAS inhibitor

    Also known as: PF-5045

  • Combination productGemcitabine

    Chemotherapy (antimetabolite)

    Also known as: Gemzar

  • Combination productNab-paclitaxel

    Taxane-type Chemotherapy

    Also known as: Abraxane

  • Combination productCetuximab

    Monoclonal Antibody (EGFR Inhibitor)

    Also known as: Erbitux

  • Combination productFluorouracil

    Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

    Also known as: 5-FU, 5-fluorouracil

  • Combination productOxaliplatin

    Part of FOLFOX Chemotherapy Regimen platinum based compound (alkylating agent)

    Also known as: Eloxatin

  • Combination productLeucovorin

    Part of FOLFOX chemotherapy regimen Folic Acid Analog

    Also known as: Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium

  • Combination productBevacizumab

    VEG-F inhibitor

    Also known as: Zirabev, Avastin

  • Combination productPembrolizumab

    immune checkpoint inhibitor (PD-1 inhibitor

    Also known as: Pembro, Lambrolizumab, MK-3475, Keytruda

  • Combination productSasanlimab

    immune checkpoint inhibitor (PD-1 inhibitor)

    Also known as: PF-06801591

  • Combination productpemetrexed

    Can be used in Platinum-based Chemotherapy regimen Antimetabolite

    Also known as: Alimta

  • Combination productCisplatin

    Can be used as part of Platinum-based chemotherapy regimen Platinum-based antineoplastic (alkylating agent)

    Also known as: Platinol, Cisplatinum, neoplatin

  • Combination productPaclitaxel

    Can be used in Platinum-based chemotherapy regimen Taxane

    Also known as: Taxol, Onxol

  • Combination productCarboplatin

    Can be used as part of a platinum-based chemotherapy regimen platinum containing compound (alkylating agent)

    Also known as: Paraplatin, Stricarb

  • Combination productPF-07284892

    PF-07284892 used as a combination product.

    Also known as: ARRY-558

06

What researchers measure

Primary outcomes

  1. Part 1 & 2: Incidence of Adverse Events (AEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.

    Time frame: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)

  2. PART 1 & 2: Number of participants with laboratory abnormalities

    Number of participants with laboratory test abnormalities. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy).

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  3. Part 1 & Part 2 (Dose Escalation Only): Number of participants with Dose-limiting toxicities (DLT)

    Any of the prespecified AEs that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes

    Time frame: Baseline up to 28 days

  4. Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)

    Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) for overall response rate (ORR) assessed by the Investigator.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'

Secondary outcomes

  1. Part 1 & 2: Maximum Observed Serum Concentration (Cmax)

    Evaluate the single and multiple dose PK ofPF-07985045 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: baseline through end of Cycle 1 (All cycles are 28 days except Part 2 Cohort C2/C3 which are 21 days)

  2. Part 1& 2: Time to Reach Maximum Observed Serum Concentration (Tmax)

    Evaluate the single and multiple dose PK of PF-07985045 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days except part 2 Cohort C2/C3 which are 21 days)

  3. Part 1 & 2: Serum Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Evaluate the single and multiple dose PK of PF-07985045 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days except Part 2 Cohort C2/C3 which are 21 days)

  4. Part 1 & 2: Changes in pERK levels

    Evaluates the intended mechanism of action (MoA) modulation of KRAS inhibition and target engagement effect of PF-07985045 in peripheral blood of participants with advanced solid tumor malignancies.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days except Part 2 Cohort C2/C3 which are 21 days)

  5. Objective Response - Number of Participants With Objective Response

    Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by the Investigator including overall response rate (ORR) (Part 1 only), progression free survival (PFS), and duration of response (DOR).

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years

  6. Part 1: Effect of Food on Cmax

    Evaluate the effect of food on Cmax of PF-07985045 as monotherapy.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days)

  7. Part 1: Effect of Food on Tmax

    Evaluate the effect of food on Tmax of PF-07985045 as monotherapy.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days)

  8. Part 1: Effect of Food on AUClast

    Evaluate the effect of food on AUClast of PF-07985045 as monotherapy.

    Time frame: Baseline through end of Cycle 1 (All cycles are 28 days)

07

Study locations

13 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • City of Hope (City of Hope National Medical Center, City Of Hope Medical Center)
    Duarte, California 91010, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • DFCI Chestnut Hill
    Newton, Massachusetts 02467, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • The Trustees of Columbia University and The New York and Presbyterian Hospital
    New York, New York 10032, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
    Madison, Wisconsin 53718, United States
  • University of Wisconsin Carbone Cancer Center-University Hospital
    Madison, Wisconsin 53792, United States
  • Pan American Center for Oncology Trials, LLC
    Rio Piedras, 00935, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in May 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
Dec 10, 2024
Primary completionActual
May 12, 2026
CompletionActual
May 12, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704724
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 10, 2024
Primary completion
May 12, 2026
Completion
May 12, 2026
Last update
May 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion